Cryoport, Inc. (CYRX) key performance indicators and operating metrics (14 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Total Gross Margin | 45.80 percent | FY2026-Q1 |
| BioStorage and BioServices Revenue | 5.2M | FY2026-Q1 |
| Gross Margin for Life Sciences Products | 41.90 percent | FY2026-Q1 |
| Gross Margin for Life Sciences Services | 48.90 percent | FY2026-Q1 |
| Revenue From the Support of Commercial Cell and Gene Therapies | 9.1M | FY2026-Q1 |
| Commercial Therapies Supported | 20.00 | FY2025-Q4 |
| Life Sciences Products Gross Margin | 46.80 percent | FY2025-Q4 |
| Life Sciences Services Gross Margin | 48.60 percent | FY2025-Q4 |
| Life Sciences Products Revenue | 20M | FY2025-Q3 |
| Life Sciences Services Revenue | 24.3M | FY2025-Q3 |
| Global Clinical Trials Supported | 745.00 | FY2025-Q3 |
| Phase 3 Clinical Trials Supported | 83.00 | FY2025-Q3 |
| Global Clinical Trials Supported (Total) | 701.00 | FY2024-Q4 |
| Total Commercial Therapy Count | 19.00 | FY2024-Q4 |
Back to CYRX overview · CYRX earnings · CYRX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.